Lipoprotein Management in Patients with Cardiometabolic Risk

In a patient with insulin resistance or type 2 diabetes, a normal-looking LDL cholesterol can be dangerously reassuring. This joint ADA/ACC consensus report, more than fifteen years ago, named the problem and proposed a fix that the field is only now fully adopting.

The trap is biological. In cardiometabolic disease, LDL particles tend to become small and dense — so a patient can carry a large number of atherogenic particles while the cholesterol content those particles hold (the LDL-C the standard test measures) looks acceptable. The panel’s argument was that in these patients you should count the particles directly. It moved beyond LDL-C to non-HDL cholesterol and, notably, apolipoprotein B — which measures one atherogenic particle each — and proposed treatment targets for them in high-risk patients.

This is why the document’s clinical significance outruns its formal evidence grade. It was an early, authoritative push toward apoB at a time when most guidelines still treated LDL-C as the only number that mattered — and the patients it focused on, those with metabolic risk, are precisely the ones in whom LDL-C most often misleads.

The honest limitation is the era. Written before the large PCSK9 and apoB outcome data and before measurement standardization matured, it was ahead of the trials that would later vindicate its central idea.

We rate the evidence moderate as a consensus document, but its place in the lineage is larger than that score suggests: it helped start the shift from measuring cholesterol to counting the particles that actually drive the disease.